Two clinical-stage biotechs are potentially the next acquisition targets in biopharma, according to Wednesday afternoon reports from Bloomberg News.
T cell engager biotech Janux Therapeutics is said to be weighing a possible sale, according to one report from the news service. Meanwhile, immune drug developer Alpine Immune Sciences is also exploring a sale as it receives takeover interest, per another Bloomberg report.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.